Abstract
With the rapid development of high-throughput techniques for identifying novel specific molecular targets in human cancer over the past few years, attention to targeted cancer therapy has dramatically increased. The term "targeted cancer therapy" refers to a new generation of drugs designed to interfere with a specific molecular target that is believed to play a critical role in tumor growth or progression, is not expressed significantly in normal cells, and is correlated with clinical outcome. There has been a rapid increase in the identification of targets that have potential therapeutic application. The clinical success of the small-molecule kinase inhibitor imatinib mesylate in chronic myeloid leukemia and gastrointestinal stromal tumors has accelerated the development of a new era of molecular targeted cancer therapy. The number of agents under preclinical and clinical investigation has grown accordingly. This emphasis on molecular biology and genetics has also resulted in significant changes in the treatment of gynecologic cancers. Several promising drugs targeting tyrosine kinases (EGFR and Her-2/Neu), mTOR, Raf kinase, proteasome, and histone deacetylases, as well as drugs affecting apoptosis and mitosis, are under development for clinical application. However, some clinical trials of p53 gene therapies and farnesyl transferase inhibitors have had limited success. In this review, we will focus on potential novel targets in gynecologic cancer and the development of targeted therapy and its clinical applications in gynecologic cancer.
Keywords: Targeted therapy, cervical cancer, endometrial cancer, ovarian cancer, clinical trials, anticancer drugs
Current Cancer Drug Targets
Title: Targeted Therapies in Gynecologic Cancers
Volume: 6 Issue: 4
Author(s): Hye S. Chon, Wei Hu and John J. Kavanagh
Affiliation:
Keywords: Targeted therapy, cervical cancer, endometrial cancer, ovarian cancer, clinical trials, anticancer drugs
Abstract: With the rapid development of high-throughput techniques for identifying novel specific molecular targets in human cancer over the past few years, attention to targeted cancer therapy has dramatically increased. The term "targeted cancer therapy" refers to a new generation of drugs designed to interfere with a specific molecular target that is believed to play a critical role in tumor growth or progression, is not expressed significantly in normal cells, and is correlated with clinical outcome. There has been a rapid increase in the identification of targets that have potential therapeutic application. The clinical success of the small-molecule kinase inhibitor imatinib mesylate in chronic myeloid leukemia and gastrointestinal stromal tumors has accelerated the development of a new era of molecular targeted cancer therapy. The number of agents under preclinical and clinical investigation has grown accordingly. This emphasis on molecular biology and genetics has also resulted in significant changes in the treatment of gynecologic cancers. Several promising drugs targeting tyrosine kinases (EGFR and Her-2/Neu), mTOR, Raf kinase, proteasome, and histone deacetylases, as well as drugs affecting apoptosis and mitosis, are under development for clinical application. However, some clinical trials of p53 gene therapies and farnesyl transferase inhibitors have had limited success. In this review, we will focus on potential novel targets in gynecologic cancer and the development of targeted therapy and its clinical applications in gynecologic cancer.
Export Options
About this article
Cite this article as:
Chon S. Hye, Hu Wei and Kavanagh J. John, Targeted Therapies in Gynecologic Cancers, Current Cancer Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/156800906777441799
DOI https://dx.doi.org/10.2174/156800906777441799 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Bioactive Polysaccharides From Natural Resources For Cancer Therapy
Bioactive polysaccharides from natural resources exhibit diverse therapeutic properties including anticancer, antioxidant, antidiabetic, immunostimulatory activity, and promotion of wound healing. In the past decades, most studies focused on the extraction and identification of polysaccharides, as well as their biological activities. A large number of bioactive polysaccharides with different structural features ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Innovative Drug Research Propelling a New Era of Precision Oncology
Drug-oncology research is leading a new era of precision medicine, becoming a frontier hotspot in cancer treatment. Advancements in molecular biology, genomics, and medicinal chemistry have driven revolutionary changes in cancer cognition and treatment strategies. Gene-targeted drugs provide more precise treatments, improving survival rates for certain cancers. Network pharmacology offers ...read more
Novel Targets in Cancer Immunotherapy
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has greatly revolutionized therapeutic strategies in the field of cancer. Current targets of FDA-approved ICIs include CTLA-4, PD-1/PDl-1, and LAG-3. However, the prognosis of cancer patients, especially with solid tumors, remains unfavorable due to the intrinsic and acquired resistance. For the past decades, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Comparison of Colour Doppler Ultrasound and 2D Ultrasound as Promising
Prediction Methods for the Treatment effect of Patients with Advanced Cervical
Cancer
Current Medical Imaging Stimuli-responsive Carriers for Controlled Intracellular Drug Release
Current Medicinal Chemistry Research Progress of Chitosan-based Multifunctional Nanoparticles in Cancer Targeted Therapy
Current Medicinal Chemistry Implications of the Dominant Role of Transporters in Drug Uptake by Cells
Current Topics in Medicinal Chemistry Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Metal Transport and Homeostasis within the Human Body: Toxicity Associated with Transport Abnormalities
Current Medicinal Chemistry Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening Protective Mechanisms of Helminths Against Reactive Oxygen Species are Highly Promising Drug Targets
Current Medicinal Chemistry Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Identifying and Validating Oncology Therapeutic Targets in the Post- Genomics Era
Current Genomics Inhibition of the Tissue Factor Coagulation Pathway
Current Vascular Pharmacology Development of Heparanase Inhibitors for Anti-Cancer Therapy
Current Medicinal Chemistry The Oncogenic Functions of Insulin-like Growth Factor 2 mRNA-Binding Protein 3 in Human Carcinomas
Current Pharmaceutical Design Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Production and Application of Copper Radiopharmaceuticals
Current Radiopharmaceuticals Advances on Quinazoline Based Congeners for Anticancer Potential
Current Organic Chemistry Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology